Monitor the upcoming annual meeting vote outcome for board control. The heavily pro-management analyst consensus (88% bullish) and the dissident's small 0.7% stake suggest management slate is favored, but the activist escalation via cross-filings (amplifier verdicts) keeps uncertainty elevated. Stock may remain range-bound until the vote is certified.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 9 $0.5800entry
- T+1 · 5mo ago +1.72%α +3.30% · $0.5900
- T+5 · 5mo ago −2.59%α −4.39% · $0.5650
- T+20 · 4mo ago −5.14%α −6.53% · $0.5502
- T+60 · 3mo ago −15.43%α −19.51% · $0.4905
Price Chart
How similar events traded
Executive Summary
Vaxart has filed definitive additional proxy soliciting materials (DEFA14A) urging shareholders to vote FOR all six of the board's director nominees and WITHHOLD on the three nominees proposed by dissident stockholder Daniel P. Houle. The filing is a social media campaign reinforcing management's stance in the ongoing contested director election for the 2026 annual meeting.
Key Financial Metrics
Key Facts
- Contested director election: management slate of 6 nominees vs. dissident slate of 3 nominees from Daniel P. Houle
- Board unanimously recommends voting FOR all six management nominees on the WHITE proxy card
- Dissident nominees characterized as lacking relevant biotech experience with ~0.7% ownership stake per prior filing
- This is definitive additional soliciting material (DEFA14A), escalating from the preliminary PREC14A filed 20 days ago
Financial Impact
No financial figures in filing; impact depends on proxy contest outcome. If dissident slate prevails, potential board composition change and strategy shift.
Risk Factors
- Dissident slate could win board seats if retail shareholders break for Houle's nominees
- Protracted proxy contest could distract management from vaccine development milestones
- Vaxart is a clinical-stage biotech with no approved products; governance uncertainty adds overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-066368 |
| Document: 0001213900-26-066368-index-headers.html | 0001213900-26-066368 |
| Document: 0001213900-26-066368-index.html | 0001213900-26-066368 |
| Document: 0001213900-26-066368.txt | 0001213900-26-066368 |
Track record
23 reports on VXRT
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
- Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
- Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
- Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
- Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
- Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers